IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 2, Issue 2, March 2022
Impact Factor: 6.252

Liposomes as a Novel Drug Delivery System

Ms. Shubhangi Manikpriya[1], Mr. Akash Shinde[2], Dr. Gajanan Sanap[3], Mr. Aniket Bankar[4], Mr. Shubham Girnare[5]
Assistant Professor, Department of Pharmaceutical Chemistry[1]
Students, Department of Pharmacy[2,4,5]
Principal, Department of Pharmacy[3]
Late Bhagirathi Yashwantrao Pathrikar College of Pharmacy, Pathri, Aurangabad, Maharashtra, India

Abstract: *Liposomes and liposome-derived nanovesicles including archaeosomes and virosomes have turn out to be essential service structures in vaccine improvement and the hobby for liposome-primarily primarily based totally absolutely sincerely vaccines has markedly increased. A key gain of liposomes, archaeosomes and virosomes. In general, and liposome-primarily based totally sincerely vaccine transport structures in particular, is their versatility and plasticity. Liposome composition and training may be selected to attain preferred capabilities including choice of lipid, charge, length, length distribution, entrapment and region of antigens or adjuvants. Depending on the chemical properties, water- soluble antigens (proteins, peptides, nucleic acids, carbohydrates, haptens) are entrapped withinside the aqueous inner region of liposomes, at the equal time as lipophilic compounds (lipopeptides, antigens, adjuvants, linker molecules) are intercalated into the lipid bilayer and antigens or adjuvants may be related to the liposome ground each via adsorption or strong chemical linking. Co-formulations containing exclusive sorts of antigens or adjuvants may be blended with the parameters stated to tailor liposomal vaccines for character applications. Special emphasis is given on this overview to cationic adjuvant liposome vaccine formulations.*

Keywords: Archaeosomes, Liposomes, Liposomal Vaccine, Therapeutic Cancer Vaccines, Veterinary, Virosomes

REFERENCES

[1]. Moser M, Leo O. Key concepts in immunology. Vaccine. 2010 Aug 31;28:C2-13.
[2]. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nature immunology. 2010 May;11(5):373-84.
[3]. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nature reviews immunology. 2013 Apr;13(4):227-42.
[4]. Smith DM, Simon JK, Baker Jr JR. Applications of nanotechnology for immunology. Nature Reviews Immunology. 2013 Aug;13(8):592-605.
[5]. Alving CR, Peachman KK, Rao M, Reed SG. Adjuvants for human vaccines. Current opinion in immunology. 2012 Jun 1;24(3):310-5.
[6]. Joshi MD, Unger WJ, Storm G, Van Kooyk Y, Mastrobattista E. Targeting tumor antigens to dendritic cells using particulate carriers. Journal of Controlled Release. 2012 Jul 10;161(1):25-37.
[7]. Leroux-Roels G. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine. 2010 Aug 31;28:C25-36.
[8]. Watson DS, Endsley AN, Huang L. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell- mediated immune responses to liposome associated antigens. Vaccine. 2012 Mar 16;30(13):2256-72.
[9]. Heegaard PM, Dedieu L, Johnson N, Le Potier MF, Mockey M, Mutinelli F, Vahlenkamp T, Vascellari M, Sørensen NS. Adjuvants and delivery systems in veterinary vaccinology: current state and future developments. Archives of virology. 2011 Feb;156(2):183-202.
[10]. Allison AC, Gregoriadis G. Liposomes as immunological adjuvants. Nature. 1974 Nov;252(5480):252-.
[11]. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nature reviews Drug discovery. 2005

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 2, Issue 2, March 2022
Impact Factor: 6.252

Feb;4(2):145-60.

[12]. Oussoren C, Zuidema J, Crommelin DJ, Storm G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection I. Influence of the anatomical site of injection. Journal of Liposome Research. 1997 Jan 1;7(1):85-99.

[13]. Henriksen-Lacey M, Bramwell VW, Christensen D, Agger EM, Andersen P, Perrie Y. Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. Journal of controlled release. 2010 Mar 3;142(2):180-6.

[14]. Carstens MG, Camps MG, Henriksen-Lacey M, Franken K, Ottenhoff TH, Perrie Y, Bouwstra JA, Ossendorp F, Jiskoot W. Effect of vesicle size on tissue localization and immunogenicity of liposomal DNA vaccines. Vaccine. 2011 Jun 24;29(29-30):4761-70.

[15]. Kaur R, Bramwell VW, Kirby DJ, Perrie Y. Pegylation of DDA: TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses. Journal of controlled release. 2012 Feb 28;158(1):72-7.

[16]. Badiee A, Khamesipour A, Samiei A, Soroush D, Shargh VH, Kheiri MT, Barkhordari F, Mc Master WR, Mahboudi F, Jaafari MR. The role of liposome size on the type of immune response induced in BALB/c mice against leishmaniasis: rgp63 as a model antigen. Experimental parasitology. 2012 Dec 1;132(4):403-9.

[17]. Yanasarn N, Sloat BR, Cui Z. Negatively charged liposomes show potent adjuvant activity when simply admixed with protein antigens. Molecular pharmaceutics. 2011 Aug 1;8(4):1174-85.

[18]. Ludewig B, Barchiesi F, Pericin M, Zinkernagel RM, Hengartner H, Schwendener RA. In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective antiviral and anti-tumour immunity. Vaccine. 2000 Aug 15;19(1):23-32.

[19]. Engler OB, Schwendener RA, Dai WJ, Wölk B, Pichler W, Moradpour D, Brunner T, Cerny A. A liposomal peptide vaccine inducing CD8+ T cells in HLA-A2. 1 transgenic mice, which recognise human cells encoding hepatitis C virus (HCV) proteins. Vaccine. 2004 Nov 15;23(1):58- 68.

[20]. Moon JJ, Suh H, Bershteyn A, Stephan MT, Liu H, Huang B, Sohail M, Luo S, Ho Um S, Khant H, Goodwin JT. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nature materials. 2011 Mar;10(3):243-51.

[21]. Quer CB, Elsharkawy A, Romeijn S, Kros A, Jiskoot W. Cationic liposomes as adjuvants for influenza hemagglutinin: more than charge alone. European journal of pharmaceutics and biopharmaceutics. 2012 Jun 1;81(2):294-302.

[22]. Watson DS, Platt VM, Cao L, Venditto VJ, Szoka Jr FC. Antibody response to polyhistidine-tagged peptide and protein antigens attached to liposomes via lipid-linked nitrilotriacetic acid in mice. Clinical and Vaccine Immunology. 2011 Feb;18(2):289-97.

[23]. Irache JM, Salman HH, Gamazo C, Espuelas S. Mannose-targeted systems for the delivery of therapeutics. Expert opinion on drug delivery. 2008 Jun 1;5(6):703-24.

[24]. Mizuuchi M, Hirohashi Y, Torigoe T, Kuroda T, Yasuda K, Shimizu Y, Saito T, Sato N. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses. Experimental and molecular pathology. 2012 Feb 1;92(1):185-90.

[25]. Senchi K, Matsunaga S, Hasegawa H, Kimura H, Ryo A. Development of oligomannose-coated liposome-based nasal vaccine against human parainfluenza virus type 3. Frontiers in microbiology. 2013 Nov 26;4:346.

[26]. Li P, Chen S, Jiang Y, Jiang J, Zhang Z, Sun X. Dendritic cell targeted liposomes–protamine–DNA complexes mediated by synthetic mannosylated cholestrol as a potential carrier for DNA vaccine. Nanotechnology. 2013 Jun 25;24(29):295101.

[27]. Taneichi M, Tanaka Y, Kakiuchi T, Uchida T. Liposome-coupled peptides induce long-lived memory CD8+ T cells without CD4+ T cells. PLoS One. 2010 Nov 30;5(11):e15091.

[28]. Ichihashi T, Satoh T, Sugimoto C, Kajino K. Emulsified phosphatidylserine, simple and effective peptide carrier for induction of potent epitope- specific T cell responses. PLoS One. 2013 Mar 22;8(3):e60068.

[29]. Takagi A, Kobayashi N, Taneichi M, Uchida T, Akatsuka T. Coupling to the surface of liposomes alters the immunogenicity of hepatitis C virus- derived peptides and confers sterile immunity. Biochemical and Biophysical Research Communications. 2013 Jan 4;430(1):183-9.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 2, Issue 2, March 2022
Impact Factor: 6.252

[30]. Nagill R, Kaur S. Enhanced efficacy and immunogenicity of 78ákDa antigen formulated in various adjuvants against murine visceral leishmaniasis. Vaccine. 2010 May 21;28(23):4002-12.

[31]. Bal SM, Hortensius S, Ding Z, Jiskoot W, Bouwstra JA. Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination. Vaccine. 2011 Jan 29;29(5):1045-52.

[32]. Gupta PN, Vyas SP. Investigation of lectinized liposomes as M-cell targeted carrier-adjuvant for mucosal immunization. Colloids and surfaces B: Biointerfaces. 2011 Jan 1;82(1):118-25.

[33]. Figueiredo L, Cadete A, Gonçalves LM, Corvo ML, Almeida AJ. Intranasal immunisation of mice against Streptococcus equi using positively charged nanoparticulate carrier systems. Vaccine. 2012 Oct 12;30(46):6551-8.

[34]. Hebishima T, Yuba E, Kono K, Takeshima SN, Ito Y, Aida Y. The pH-sensitive fusogenic 3-methyl-glutarylated hyperbranched poly (glycidol)- conjugated liposome induces antigen-specific cellular and humoral immunity. Clinical and Vaccine Immunology. 2012 Sep;19(9):1492-8.

[35]. Ding Q, Chen J, Wei X, Sun W, Mai J, Yang Y, Xu Y. RAFTsomes containing epitope-MHC-II complexes mediated CD4+ T cell activation and antigen-specific immune responses. Pharmaceutical research. 2013 Jan;30(1):60-9.

[36]. Rodriguez AE, Zamorano P, Wilkowsky S, Torrá F, Ferreri L, Dominguez M, Florin-Christensen M. Delivery of recombinant vaccines against bovine herpesvirus type 1 gD and Babesia bovis MSA-2c to mice using liposomes derived from egg yolk lipids. The Veterinary Journal. 2013 Jun 1;196(3):550-1.

[37]. Liu J, Wu J, Wang B, Zeng S, Qi F, Lu C, Kimura Y, Liu B. Oral vaccination with a liposome-encapsulated influenza DNA vaccine protects mice against respiratory challenge infection. Journal of medical virology. 2014 May;86(5):886-94.

[38]. Ribeiro AM, Souza AC, Amaral AC, Vasconcelos NM, Jeronimo MS, Carneiro FP, Faccioli LH, Felipe MS, Silva CL, Bocca AL.Nanobiotechnological approaches to delivery of DNA vaccine against fungal infection. Journal of biomedical nanotechnology. 2013 Feb 1;9(2):221-30.

[39]. Amidi M, de Raad M, Crommelin DJ, Hennink WE, Mastrobattista E. Antigen-expressing immunostimulatory liposomes as a genetically programmable synthetic vaccine. Systems and synthetic biology. 2011 Jun;5(1):21-31.

[40]. Pichon C, Midoux P. Mannosylated and histidylated LPR technology for vaccination with tumor antigen mRNA. Synthetic Messenger RNA and Cell Metabolism Modulation. 2013:247-74.

[41]. Li Y, Hu Y, Jin Y, Zhang G, Wong J, Sun LQ, Wang M. Prophylactic, therapeutic and immune enhancement effect of liposome-encapsulated PolyICLC on highly pathogenic H5N1 influenza infection. The journal of gene medicine. 2011 Jan;13(1):60-72.

[42]. Acres B, Limacher JM. MUC1 as a target antigen for cancer immunotherapy. Expert review of vaccines. 2005 Aug 1;4(4):493-502.

[43]. Sarkar, S., Salyer, A., Wall, K., Sucheck, S. (2013) Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l- rhamnose displaying liposomes. Bioconjug Chem 24: 363–375.

[44]. Lakshminarayanan V, Thompson P, Wolfert MA, Buskas T, Bradley JM, Pathangey LB, Madsen CS, Cohen PA, Gendler SJ, Boons GJ. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proceedings of the National Academy of Sciences. 2012 Jan 3;109(1):261-6.

[45]. North S, Butts C. Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers. Expert Review of Vaccines. 2005 Jun 1;4(3):249-57.

[46]. Butts C, Murray RN, Smith CJ, Ellis PM, Jasas K, Maksymiuk A, Goss G, Ely G, Beier F, Soulières D. A Multicenter Open-Label Study to Assess the Safety of a New Formulation of BLP25 Liposome Vaccine in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 2010 Nov 1;11(6):391-5.

[47]. Wu YL, Park K, Soo RA, Sun Y, Tyroller K, Wages D, Ely G, Yang JC, Mok T. INSPIRE: a phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC cancer. 2011 Dec;11(1):1-7.

[48]. Ohyanagi F, Horai T, Sekine I, Yamamoto N, Nakagawa K, Nishio M, Senger S, Morsli N, Tamura T. Safety of BLP25 liposome vaccine (L- BLP25) in Japanese patients with unresectable stage III NSCLC after primary

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 2, Issue 2, March 2022
Impact Factor: 6.252

chemoradiotherapy: preliminary results from a Phase I/II study. Japanese journal of clinical oncology. 2011 May 1;41(5):718-22.

[49]. Kozako T, Arima N, Yoshimitsu M, Honda SI, Soeda S. Liposomes and nanotechnology in drug development: focus on oncotargets. International Journal of Nanomedicine. 2012;7:4943.

[50]. Woese CR, Fox GE. Phylogenetic structure of the prokaryotic domain: the primary kingdoms. Proceedings of the National Academy of Sciences. 1977 Nov 1;74(11):5088-90.

[51]. Pang Y, Zhang Y, Wang H, Jin J, Piao J, Piao J, Liu Q, Li W. Reduction of Salmonella enteritidis number after infections by immunization of liposome-associated recombinant SefA. Avian diseases. 2013 Sep;57(3):627-33.

[52]. Krishnan L, Sprott GD. Archaeosome adjuvants: immunological capabilities and mechanism (s) of action. Vaccine. 2008 Apr 16;26(17):2043- 55.

[53]. Almeida J, Edwards DC, Brand C, Heath T. Formation of virosomes from influenza subunits and liposomes. The Lancet. 1975 Nov 8;306(7941):899-901.

[54]. Glück R. Immunopotentiating reconstituted influenza virosomes (IRIVs) and other adjuvants for improved presentation of small antigens. Vaccine. 1992 Jan 1;10(13):915-9.

[55]. Zamparo E, Little D. Immunogenicity and effectiveness of virosomal adjuvanted vaccines against influenza: a brief review of their utility in the elderly population. J Prev Med Hyg. 2011 Sep 1;52(3):116-9.

[56]. Ambrosch F, Wiedermann G, Jonas S, Althaus B, Finkel B, Glück R, Herzog C. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine. 1997 Aug 1;15(11):1209-13.

[57]. Saksawad R, Likitnukul S, Warachit B, Hanvivatvong O, Poovorawan Y, Puripokai P. Immunogenicity and safety of a pediatric dose virosomal hepatitis A vaccine in Thai HIV-infected children. Vaccine. 2011 Jun 24;29(29-30):4735-8.

[58]. De Bernardis F, Amacker M, Arancia S, Sandini S, Gremion C, Zurbriggen R, Moser C, Cassone A. A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models. Vaccine. 2012 Jun 22;30(30):4490-8.

[59]. Walczak M, de Mare A, Riezebos-Brilman A, Regts J, Hoogeboom BN, Visser JT, Fiedler M, Jansen-Dürr P, van der Zee AG, Nijman HW, Wilschut J. Heterologous prime-boost immunizations with a virosomal and an alphavirus replicon vaccine. Molecular pharmaceutics. 2011 Feb 7;8(1):65-77.

[60]. Moser C, Müller M, Kaeser MD, Weydemann U, Amacker M. Influenza virosomes as vaccine adjuvant and carrier system. Expert review of vaccines. 2013 Jul 1;12(7):779-91.

[61]. Liu H, de Vries-Idema J, Ter Veer W, Wilschut J, Huckriede A. Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing. Medical microbiology and immunology. 2014 Feb;203(1):47-55.

[62]. Kamphuis T, Stegmann T, Meijerhof T, Wilschut J, de Haan A. A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats. Influenza and other respiratory viruses. 2013 Nov;7(6):1227-36.

[63]. Jamali A, Holtrop M, de Haan A, Hashemi H, Shenagari M, Memarnejadian A, Roohvand F, Sabahi F, Kheiri MT, Huckriede A. Cationic influenza virosomes as an adjuvanted delivery system for CTL induction by DNA vaccination. Immunology letters. 2012 Nov 1;148(1):77-82.

[64]. Kheiri MT, Jamali A, Shenagari M, Hashemi H, Sabahi F, Atyabi F, Saghiri R. Influenza virosome/DNA vaccine complex as a new formulation to induce intra-subtypic protection against influenza virus challenge. Antiviral research. 2012 Sep 1;95(3):229-36.

[65]. Peduzzi E, Westerfeld N, Zurbriggen R, Pluschke G, Daubenberger CA. Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial. Clinical Immunology. 2008 May 1;127(2):188-97.

[66]. Tamborrini M, Stoffel SA, Westerfeld N, Amacker M, Theisen M, Zurbriggen R, Pluschke G. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations. Malaria journal. 2011 Dec;10(1):1-1.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 2, Issue 2, March 2022
Impact Factor: 6.252